January 31, 2020
21 min.

Description

The FDA recently expanded the indications for transcatheter aortic valve replacement (TAVR) to include patients at low surgical risk, but experts are urging caution about which low-risk patients should undergo TAVR until more information is gathered. In this episode, Joseph E. Bavaria, MD, explored recent clinical trials with Tsuyoshi Kaneko, MD, Michael J. Reardon, MD, and Vinod Thourani, MD. They discussed what these trials mean for cardiac surgeons, interventional cardiologists, and the heart team, as well as knowledge gaps about age, bicuspid patients, SYNTAX score, pacemakers, and mechanical valve durability.